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Abstract
Introduction: Breast cancer is genetically and clinically a heterogeneous disease. However, the exact contribution of 
different cell types and oncogenic mutations to this heterogeneity are not well understood. Recently, we discovered an 
interaction between Wnt and integrin-linked kinase (ILK) within the signaling cascade that regulates cell growth and 
survival. Interestingly, mammary-specific expression of either one of these proteins has been shown to promote 
mammary tumorigenesis. In light of our recent findings and to investigate the potential interaction between Wnt and 
ILK proteins during mammary tumor formation and progression, we established a transgenic mouse model that 
expresses both Wnt and ILK in mammary epithelial cells.
Methods: A novel transgenic mouse model with mammary-specific expression of both Wnt1 and ILK was generated 
by crossing the two previously characterized mouse models, MMTV-Wnt1 and MMTV-ILK. The resulting MMTV-Wnt/ILK 
mice were closely monitored for tumor development and growth, as well as for the tumor onset. The molecular 
phenotypes of both tumors and premalignant mammary glands were investigated by using biochemical and global 
gene-expression analysis approaches.
Results: A significant acceleration in mammary tumor incidence and growth was observed in the MMTV-Wnt/ILK 
mice. Pre-neoplastic mammary glands also display lobuloalveolar hyperplasia and an increase in ductal epithelium 
proliferation. Apart from elevated expression of Wnt/ILK targets, such as β-catenin and cyclin D1, gene-expression 
profiling identified the surprising activation of the FOXA1 transcription factor. Upregulation of FOXA1, which is also 
known as the molecular marker of differentiated mammary luminal cells, was consistent with the expansion of the 
enriched luminal progenitor population or CD29loCD24hiCD61+ cells in MMTV-Wnt/ILK tumors.
Conclusions: These results show cooperation between Wnt1 and ILK transgenes during mammary carcinogenesis, 
leading to changes in a transcriptional network, which could dictate a specific breast cancer phenotype with 
enhanced growth dynamics. The MMTV-Wnt/ILK can be used as a model to identify further the genes downstream of 
the estrogen receptor-β/FOXA1 and to investigate the mechanisms targeting the expansion of the luminal progenitor 
cells leading to hyperplasia and tumorigenesis.
Introduction
The oncogenic conversion of a primary epithelial cell to a
malignant tumor involves cooperation between multiple
signaling pathways, including the activation of growth-
promoting signals and the inactivation of tumor-suppres-
sor genes [1]. In breast cancer, a complex molecular inter-
play involving multiple signaling pathways, including
Wnt signaling cascade [2], has been attributed to the
development of this disease [3]. The Wnts comprise of a
large family of secreted glycoproteins that affect diverse
processes such as gene transcription, cell adhesion, and
cell polarity [4]. The highly conserved canonic Wnt/β-
catenin pathway activates β-catenin-dependent gene
expression by regulating stabilization and nuclear accu-
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mulation of β-catenin, a protein originally identified as a
component of intercellular junctions [5]. In the absence
of the Wnt ligand, cytoplasmic β-catenin level is kept low
through phosphorylation and ubiquitin-mediated prote-
osomal degradation by a multiprotein complex composed
primarily of GSK-3β, Axin, and adenomatous polyposis
coli (APC) (reviewed in [4,6]).
To date, evidence for mutations in the Wnt signaling-
pathway components in breast cancer is lacking. How-
ever, various lines of evidence suggest that in breast can-
cer, Wnt signaling may be deregulated by loss of
expression of negative-pathway regulators such as
secreted Frizzled-related protein 1 (sFRP1), which is
downregulated in many human breast tumors and is
associated with poor prognosis [2,7]. Wnt-induced
expansion of progenitor cells in mammary tumor devel-
opment was recently identified [8-10]. In addition, stabili-
zation of β-catenin and amplification of its target gene,
cyclin D1, is documented in > 50% of breast carcinomas
[11,12], suggesting that the downstream effectors of the
Wnt cascade could also be activated through abnormali-
ties in other signaling pathways. Integrin-linked kinase
(ILK)-mediated signaling is one such pathway. ILK is a
cytoplasmic effector of integrin receptors and is involved
in oncogenesis through the induction of antiapoptotic
pathways and cell-cycle progression [13,14]. Overexpres-
sion of constitutively active ILK in epithelial cells results
in simultaneous inhibition of GSK-β activity and translo-
c a t i o n  o f  β - c a t e n i n  t o  t h e  n u c l e u s ,  f o l l o w e d  b y  a n
increase in β-catenin/Tcf transcriptional activity. Addi-
tionally, inhibition of ILK in colon carcinoma cells with
constitutively active nuclear β-catenin resulted in inhibi-
tion of β-catenin/TCF transcriptional activity (reviewed
in [15]). A similar correlation also was reported in human
colon cancer between ILK expression, activation of β-
catenin, and tumor progression in vivo [16]. In addition
to the effect of ILK on the downstream components of
the Wnt pathway in the absence of Wnt signaling, we
demonstrated a significant reduction in Wnt-induced
nuclear accumulation of β-catenin on ILK inactivation.
Our results suggest a potential role of ILK in the regula-
tion of Wnt-mediated β-catenin turnover and nuclear
accumulation [17].
In light of these recent findings, and the fact that ILK
activation and overexpression can promote oncogenic
phenotypes in both cell-culture and transgenic mouse
models [13], we have initiated in vivo experiments to
determine whether ILK and Wnt signaling pathways
interact to modulate tumor formation and progression.
We have generated double transgenic mice that overex-
press both ILK and Wnt1 in mammary glands. The
MMTV-Wnt1 transgenic mice have been used exten-
sively as a model of breast cancer development and pro-
gression [8,18,19]. Interestingly, MMTV-Wnt1-driven
tumors show an enhancement in ILK expression and a
requirement for ILK activity for cyclin D1 upregulation
[20]. This suggests that overexpression of ILK may be
required, not only for the initiation of premalignant
changes, but also for the maintenance of the malignant
phenotypes driven by Wnt signaling. MMTV-ILK trans-
genic mice also develop premalignant changes such as
hyperplasia, as well as tumor formation, which occur
with a much longer latency than in the MMTV-Wnt1
mice [21]. ILK overexpression has been reported in many
human cancers, with a positive correlation with cancer
growth and an inverse correlation with survival [22-24].
To test the in vivo functional significance of possible
crosstalk between ILK and Wnt1 signaling pathways, we
used a transgenic approach. Double-transgenic mice
were generated that express both Wnt1 and Ilk transgenes
in mammary epithelium under the mouse mammary
tumor virus (MMTV)-long terminal repeat (LTR) pro-
moter.
Here we report a significant acceleration in tumor
onset, development, and growth rate in MMTV-Wnt/ILK
double-transgenic mice as well as a profound enhance-
ment in pre-neoplastic mammary gland hyperplasia. In
addition, we provide unanticipated, novel evidence sug-
gesting cooperation between the Wnt1 and ILK path-
ways, resulting in upregulation of FOXA1/ER-α
transcriptional network and the expansion of the luminal
progenitor cells, leading to accelerated breast cancer
development.
Materials and methods
Generation of MMTV-Wnt/ILK transgenic mice
M M T V - W n t 1  ( a  g i f t  f r o m  D r .  H a r o l d  V a r m u s )  a n d
MMTV-ILK [21] mice were backcrossed to the FVB
strain. MMTV-Wnt1 males were then bred with MMTV-
ILK female to generate the double-transgenic MMTV-
Wnt/ILK mice. Mice were tail clipped and genotyped by
PCR by using forward 5'-CCACACAGGCATAGAGT-
GTCTGC -3' and reverse 5'-GGACTTGCTTCT-
TATAGCC-3' primers for Wnt1  transgene [25] and
forward 5'-CATGTATGCACCTGCCTG-3' and reverse
5'- TATGTCACACCACAGAAG 3' primers for the ILK
transgene [21]. Nulliparous females were monitored
biweekly for the appearance of a small palpable tumor
nodule in the mammary fat pads. Ages were recorded at
the time of tumor discovery and tumors were measured
every 2 to 3 days with a calliper by using the modified
ellipsoid formula (LxW2)/2 [26]. All animal procedures
were done in accordance with protocols approved by the
Institution Animal Care Committee at the Jack Bell
Research Centre and University of British Columbia in
Vancouver.Oloumi et al. Breast Cancer Research 2010, 12:R38
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Whole-mount mammary glands, histology, and 
immunohistochemistry
For whole-mount staining, the fourth mammary glands
from transgenic and control mice were harvested and
fixed in Carnoy's fixative (60% ethanol, 30% chloroform,
10% acetic acid) for 2 to 4 h, rehydrated and stained in
carmine alum (Stem Cell Technologies, Vancouver, BC,
Canada) overnight. After dehydration, samples were
spread on a microscope slide, cleared in xylene, and
images were acquired by using a dissecting microscope.
For histologic analysis, mammary and tumor tissue sam-
ples were fixed in 10% neutral buffer formalin overnight
at room temperature and were subsequently rinsed and
kept in 70% ethanol until embedded in paraffin and sec-
t io ned a t  5-μ m  t hi ckness.  Secti ons  we r e  e it he r s tai ned
with hematoxylin and eosin (H&E) or processed for
immunohistochemical analysis and counterstained by
following standard procedures. Sections were incubated
with rabbit anti FOXA1 (Abcam ab55178, Cambridge,
MA), monoclonal β-catenin (BD-610153), polyclonal
CD24 (BD-557436) (BD Transduction Laboratories, Mis-
sissauga, ON, USA), monoclonal PCNA (sc-56), poly-
clonal Ki-67 (Neomakers RM9106-S0) and polyclonal ER-
α sc-542 (Santa Cruz Biotechnology Inc., Santa Cruz,
CA) antibodies. Mouse and rabbit IgG antibodies were
used as controls (Santa Cruz Biotechnology). All antibod-
ies were used at 1:100 dilutions. Antibody binding was
detected by using the Dako Cytomation Envision System
(Dako Cytomation, Carpinteria, CA) and Vector Nova-
RED substrate kit (Vector Laboratories Inc., Burlingame,
CA), according to the manufacturer's protocol.
Preparation of tumor-cell suspension, cell sorting, and 
immunofluorescence
Tumors were finely chopped with a razor blade and then
digested in DMEM containing 10% collagenase/
hyaluronidase mixture (Stem Cell Technologies) for 1.5 h
at 37°C. Antibodies used against mouse antigens were
purchased from BD Pharmingen, unless otherwise speci-
fied, and included CD24-APC (BD-101813); CD-61-PE
(BD-555735); CD29-FITC (Biolegend-12343); biotiny-
lated CD31 (BD-553371), CD45 (Biolegend-103103),
Ter119 (Biolegend-116203); and streptavidin-PE-Texas
red (BD-551487). Antibody staining and cell sorting was
performed as previously described [8]. For labeling of
intracellular epitopes, cells were cultured on poly-L-
lysine-coated coverslips, and were fixed in 4% paraform-
aldehyde and permeabilized in 0.2% Triton-X 100 for 4
min at room temperature before blocking in 2% BSA in
PBS at room temperature for 30 min. Antibodies used
were cytokeratin 14 (Covance, PRB155P) and cytokeratin
18 (Progen Biotechnik, GP CK18.2).
Protein extraction and Western blot analysis
Mammary gland and tumor samples were flash frozen in
liquid nitrogen and lysed in buffer containing 1% Triton
X-100, 50 mM Hepes (pH = 7.5), 150 mM NaCl, 10%
glycerol, and 1 mM and 2 mM EDTA supplemented with
the appropriate protease and phosphatase inhibitor [27].
Protein concentrations were determined by using the
BCA Protein Assay (Pierce, Rockford, IL, USA) according
to the manufacturer's recommendations. Western blots
were performed by using the following antibodies: mono-
clonal β-catenin (BD Transduction Laboratories 610153),
monoclonal cyclin D1/D2 (Upstate Biotech 05-362, Lake
Placid, NY), polyclonal Ruvb-like 1 (Protein Tech. Group
10210-2-AP, Chicago, IL), and monoclonal β-actin
(Sigma A5441, St. Louis, MO) as loading control. All anti-
bodies, unless otherwise indicated, were used at 1:1,000
dilution.
Microarray
Gene-expression profiling was performed at the Centre
for Translational and Applied Genetics (CTAG, Vancou-
ver, BC, Canada) by using Affymetrix GeneChip Mouse
Exon 1.0 ST Arrays according to the manufacturer's
instructions. In brief, total RNA was extracted from the
snap-frozen tumor tissue by using the GeneChip Whole
Transcript (WT) Sense Target (ST) Labeling Assay
(Affymetrix), as per manufacturer's recommendations,
before being hybridized to a GeneChip Mouse Exon 1.0
ST Array (Affymetrix). RNA, 1 μg, was used as starting
material, and the rRNA was reduced by using the
RiboMinus Transcriptome Isolation Kit (Invitrogen), as
per Affymetrix recommendations. Each chip was run
through the GeneChip Fluidics Station 450 for washing
and staining before scanning the chip on the GeneChip
Scanner 3000 7G (Affymetrix). The corresponding
microarray data were deposited into the Gene Expression
Omnibus, with accession number GSE19300.
Quantitative RT-PCR
Quantitative real-time PCR (Q-RT-PCR) was conducted
in 384-well plates on an Applied Biosystems (Foster City,
CA, USA) Q-RT-PCR instrument by using Roche Univer-
sal Probe Library (UPL) (Roche Applied Science, Laval,
Quebec, Canada) according to the manufacturer's
instructions. In brief, 1 μg of total RNA was used in a 40-
μl reaction to make cDNA. Subsequently, 10 μl of the Q-
RT-PCR mixture containing 100 nM UPL probe, 200 nM
of each primer, and TaqMan PCR master mix (Applied
Biosystems) was loaded into each well. After preliminary
95°C incubation, the samples were read for 40 cycles
(95°C, 30 sec; 60°C, 30 sec; 72°C, 60 sec). The values for
mRNA expression were normalized by using β-actin or
GAPDH or both as the housekeeping genes. All Q-RT-
PCR primers were designed by using the Roche Applied
Science online assay design center for UPL system, and
were purchased from Invitrogen (Burlington, ON, Can-
ada). All assays were set up for a relative quantitation
m e t h o d  i n  w h i c h  m e a n  C t  v a l u e s  f r o m  M M T V - W n t 1
samples were used as calibrators for data analysis forOloumi et al. Breast Cancer Research 2010, 12:R38
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MMTV-Wnt/ILK samples. The relative fold change (FC)
of gene expression between MMTV-Wnt1 and MMTV-
Wnt/ILK samples was calculated by using the standard 2-
ΔΔct method.
Statistical analysis
All the statistical analysis was performed as specified in
this section, unless otherwise indicated in the figure leg-
ends. The percentage tumor-free data were plotted by
using Kaplan-Meier curves, and differences in tumor free
rates were assessed with the Cox model. Tumor-volume
data were analyzed by using linear regression. Affymetrix
GeneChip expression data were processed by using
ArrayAssist software (ref ArrayAssist v1.x). Probe-set
summarization and background correction of expression
values was performed by using the RMA algorithm
(ArrayAssist ExonRMA), and chip-to-chip variation was
corrected by using quantile normalization. Quantitative
R T -PCR data (cycle time or Ct data) were obtained by
using RQ Manager Software (Applied Biosystems). Ct
data were analyzed by using linear mixed effects, allowing
for the biologic sample replicates and Q-RT-PCR plate-
to-plate variation, as well as adjustment for to the refer-
ence loading control β-actin or GAPDH or both. Results
were exponentiated to obtain natural scale fold-change
estimates (that is, 2-ΔΔCt) and confidence intervals. The
null-effect reference line at 1.0 is shown in the fold-
change plots, and statistically significant fold changes are
indicated by whisker 95% confidence intervals that do not
cross the reference line. Benjamini-Hochberg (BH)
adjustment of P values to correct for multiple compari-
sons was also performed on Q-RT-PCR data, and only
genes with P value of < 0.05 were considered significantly
differentially expressed.
Results
Mammary tumor formation and growth are accelerated in 
MMTV-Wnt/ILK double-transgenic mice
To begin investigating the cooperation between ILK and
Wnt signaling pathways in mammary tumor formation
we needed to determine how overexpression of ILK
would affect Wnt1-induced mammary tumor develop-
ment. Double-transgenic MMTV-Wnt/ILK mice were
created by crossing the previously available MMTV-
W n t 1  m a l e  a n d  t h e  M M TV - I L K  f e m a l e  ( s ee  M a t e r i a l s
and Methods) (Figure 1a). In addition to genotyping to
confirm the presence of both transgenes (that is, MMTV-
Wnt1 and MMTV-ILK) (Additional file 1, Figure S1),
quantitative RT-PCR confirmed overexpression of
human ILK in tumors of the double-transgenic mice (Fig-
ure 1b), whereas the level of Wnt1 overexpression
remained fairly consistent in both transgenic models
(data not shown). After genotyping, double-transgenic
MMTV-Wnt/ILK female mice and their littermate con-
trols (MMTV-Wnt1, MMTV-ILK, and FVB) were moni-
tored and palpated weekly for the onset of tumors. The
percentage of animals in each cohort remaining free of
palpable mammary tumors was plotted at weekly inter-
vals as a function of age for virgin females (Figure 2a).
Mammary tumors appeared earlier in bi-transgenic ani-
mals overexpressing both Wnt and Ilk oncogenes. About
half of the bi-transgenic mice examined (n = 23) devel-
oped palpable mammary tumors by the age of 19 weeks
(T1/2 = 19), whereas fewer than 30% of the Wnt1 trans-
genic and none of the ILK or FVB control mice had
tumors. Furthermore, by age 50 weeks, all of the bi-trans-
genic mice exhibited tumors, at which time about 25% of
the Wnt1 transgenic mice (n = 31) still were tumor free
(Figure 2a). In addition, the tumors that arose in both
Wnt1 and Wnt/ILK transgenic mice were lobuloalveolar
adenocarcinomas, as was previously reported for the
Wnt1 transgenic mice.
To determine the growth rate after tumor onset, the
sizes of the mammary tumors were periodically mea-
sured. We observed a significant difference in the growth
rate of the mammary tumors between MMTV-Wnt1 and
Figure 1 Overexpression of the human ILK gene. (a) Mouse MMTV-
Wnt1 and human MMTV-ILK transgene constructs (b). Quantitative RT-
PCR performed on randomly selected tumors from each MMTV-Wnt1 
and MMTV-Wnt/ILK group (n = 8) showing a dramatic overexpression 
of the human ILK gene in the double-transgenic samples. The bar 
graphs show the relative amount of human ILK overexpression in the 
individual MMTV-Wnt/ILK and MMTV-Wnt1 tumors normalized for β-
actin expression. The statistical analysis with 95% confidence interval 
of (+754.18; -256.46) shows an average value of about 400-fold of over-
expression in human ILK in MMTV-Wnt/ILK with an adjusted P value of 
3.1E-16 determined by Benjamini-Hochberg test.Oloumi et al. Breast Cancer Research 2010, 12:R38
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MMTV-Wnt/ILK transgenic mice. In general, tumors
arising in MMTV-Wnt/ILK mice grew at an accelerated
rate, forming large tumors of 2,000 mm3 or more within
14 days, whereas tumors in MMTV-Wnt1 typically did
not grow to this size in 50 days (Figure 2b). Therefore,
based on the calliper measurement of individual tumors
from each group, tumors from MMTV-Wnt/ILK mice
showed a tumor-doubling time of 4 days, whereas the
doubling time of the tumors in the MMTV-Wnt1 group
was 3 times longer, averaging 12 days (Figure 2c).
Pre-neoplastic mammary glands of MMTV-Wnt/ILK mice 
show enhanced hyperplasia and proliferation
To determine whether the observed accelerated tumor
incidence starts with a higher proliferation during mam-
mary gland development, we examined the pre-neoplas-
tic mammary glands in all transgenic models. The
mammary gland architecture was therefore analyzed with
whole-mount preparation. Whereas the mammary
glands taken from a wild-type FVB female mouse
revealed a branching ductal structure typical of a virgin
female, reflected by the presence of an ordered ductal
network with side branching, the pre-neoplastic mam-
mary glands from MMTV-Wnt/ILK transgenic mice
exhibited increased ductal branching with more second-
ary and ternary side branches, as well as a denser alveolar
development at an earlier age (8 weeks old) compared
with either MMTV-Wnt1 mice or controls (10 to 12
weeks old) (Figure 3a). The areas of dense alveoli are
indicative of mammary gland hyperplasia (black arrows
in F igure 3a). In addition, the presence of hyperplastic
mammary tissue was confirmed by hematoxylin and
eosin (H&E) staining of transgenic mammary gland sec-
tions (Figure 3b, a-f). The mammary glands of MMTV-
Wnt/ILK mice showed a marked enhancement in epithe-
lial hyperplasia as well as multilayered and disorganized
ductal epithelium, compared with the mammary glands
of the MMTV-Wnt1 mice.
Immunohistochemical staining also was used to exam-
ine the pre-neoplastic mammary glands for both PCNA
(proliferating cell nuclear antigen)- and Ki67-positive
cells, two factors known to represent proliferation.
Whereas PCNA is maximally detected in the S phase,
Ki67 is preferentially expressed during later stages of the
cell cycle [28], providing different staining patterns, but
both indicative of the proliferation status of the tissue. As
previously shown [9], we also confirmed a greater prolif-
eration status in the mammary gland cells in MMTV-
W n t 1  t r a n s g e n i c  m i c e  c o m p a r e d  w i t h  n o n - t r a n s g e n i c
FVB controls (Figure 3b, g-j). However, the mammary
glands of MMTV-Wnt/ILK mice showed an even greater
increase in both PCNA (Figure 3b, g-j) and Ki67 (Figure
3c) staining over those observed in the glands of MMTV-
Wnt1 transgenic mice (Figure 3b, i-l, and 3c). Altogether,
these results suggest a further enhancement in the pro-
portion of the proliferating cells as the result of the
mutual input from both ILK and Wnt signaling pathways
in the double-transgenic mice. The pre-neoplastic mam-
mary glands of the double-transgenic mice on average
showed about a twofold increase in proliferation activity
based on Ki67 staining compared with the glands of the
MMTV-Wnt1 model (Figure 3d).
Biochemical analysis of the double-transgenic tumors 
reveals upregulation of proliferation promoting molecular 
markers
To investigate the potential role of some of the known
downstream targets of both Wnt and ILK signaling path-
ways in the enhanced development of tumors in Wnt/ILK
double-transgenic mice, we performed a series of West-
Figure 2 Mammary tumor formation and tumor growth in 
MMTV-Wnt/ILK mice. (a) Kaplan-Meier analysis of the percentage of 
tumor-free mice over time; P < 0.001. (b) Linear representation of 
growth rate from three randomly selected tumors from each transgen-
ic group shows an accelerated rate of growth in MMTV-Wnt/ILK mice. 
(c) Tumor-doubling time was calculated based on the exponential 
curve fit of the tumor-volume measurements against time. The results 
show the mean doubling time for n = 7 tumors collected in each 
group, which supports the proliferative advantage of the tumors aris-
ing in the MMTV-Wnt/ILK transgenic group. The error bars represent 
the standard error of the mean (SEM), and the **P value was calculated 
by using a paired two-sample t test with a 95% confidence interval.Oloumi et al. Breast Cancer Research 2010, 12:R38
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ern blots on protein extracts isolated from 20 randomly
chosen tumors. In addition, we included protein extracts
from two normal mammary glands harvested from FVB
mice as a control (Figure 4a). The Western-blot data were
quantified by densitometry analysis (Figure 4b). All val-
ues were normalized to β-actin for the corresponding
sample on each gel. We observed a clear difference in the
expression of some of the downstream molecular effec-
tors of the Wnt signaling pathway, such as cyclin D1, β-
catenin, and suggestive evidence of a difference for RuvB-
like 1. Western-blot analysis of β-catenin showed greater
than twofold increase in β-catenin expression in Wnt/ILK
double-transgenic tumors compared with Wnt1-induced
mammary tumors (Figure 4a,b). More interesting, β-
catenin immunohistochemical staining revealed a
marked increase in nuclear accumulation of β-catenin in
MMTV-Wnt/ILK tumors compared with a more-cyto-
plasmic distribution of β-catenin observed in Wnt1
tumors (Figure 4c). It is known that an increase in Wnt-
mediated β-catenin is attributable to increased stability
through the inhibition of the ubiquitin-mediated degra-
dation [29,30]. In MMTV-Wnt/ILK tumors, further acti-
vation of ILK, which has also been shown to regulate β-
catenin stabilization and nuclear localization (reviewed in
[15]), further contributed to this increase. Quantification
of the proportion of the cells staining positive for nuclear
β-catenin to the total number of the cells in five randomly
chosen fields of view shows a 3.5-fold increase in nuclear
positive β-catenin staining in MMTV-Wnt/ILK tumors
(Figure 4d). In addition, RuvB-like 1, a TATA box-binding
protein essential for cell growth [31], which participates
in β-catenin-mediated transactivation by binding to
nuclear β-catenin [32], also showed about a 1.8-fold
increase in MMTV-Wnt/ILK tumors. Interestingly,
RuvB-like 1 was also recently found to interact with ILK
in a proteomics analysis for the identification of the com-
ponents of the ILK interactome [33].
Previous studies have shown an increased abundance of
cyclin D1 in Wnt1 mammary tumors [34,35]. Although
cy c l i n  D 1  l ev e l s  w e r e  i n cr e as ed  i n  W n t 1  t u m o r s  c o m -
pared with normal mammary epithelium, we found an
additional fourfold increase in the cyclin D1 level in Wnt/
ILK double-transgenic mammary tumors. We also
observed an increase in GSK-3 Ser-9 phosphorylation in
MMTV-Wnt/ILK tumors. Both cyclin D1 and phospho-
rylation of GSK-3β are regulated by ILK as well as by
Wnt1 [20]. Other signaling molecules, such as P-ERK and
fibronectin, also showed a marginal increase in the
MMTV-Wnt/ILK tumor samples (Figure 4b). However,
this upregulation was not statistically significant with the
sample size tested.
Some of the other downstream targets of Wnt and ILK
pathways, such as c-myc, Lef-1, MMP-2, MMP-7 (data
not shown), ser473P-AKT (Additional file 1, Figure S2), did
Figure 3 Pre-neoplastic mammary gland analysis. (a) Whole-
mount ductal outgrowths from 10- to 12-week-old FVB, MMTV-Wnt1, 
and MMTV-ILK mice and 8-week-old MMTV-Wnt/ILK mice show a 
marked enhancement in the ductal network of MMTV-Wnt/ILK pre-
neoplastic mammary glands at an earlier age. Images were taken by 
using a dissecting microscope at 4× magnification. Black arrow shows 
an area of dense alveoli. (b) Sections from inguinal mammary glands 
of 8- to 9-week-old mice were stained with H&E and PCNA. Mammary 
gland taken from an FVB mouse shows a normal glandular epithelial 
(a,b) and minimal PCNA staining (g-h), whereas sections from MMTV-
Wnt show more hyperplasia (c,d) and more PCNA staining (i,j). Section 
of mammary glands from MMTV-Wnt/ILK mice shows an even greater 
epithelial hyperplasia, multilayered and disorganized ductal epitheli-
um (e,f), as well as a marked increase in PCNA staining (k,l). The pic-
tures are representative of at least five different stainings. Scale bars, 50 
μm. (c) Ki67 was used as an additional marker to confirm the higher 
proliferation status of the MMTV-Wnt/ILK pre-neoplastic mammary 
glands. Scale bars, 100 μm. (d) Ki67-positive staining is quantified 
based on the number of the mammary lumina containing Ki67-posi-
tive cells. At least 50 mammary lumina were counted in each condition 
in randomly selected fields of view. Data represent mean ± SD. *P < 
0.04 was calculated by using a paired two-sample t test.Oloumi et al. Breast Cancer Research 2010, 12:R38
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not show a marked difference in expression in the mam-
mary tumors between the two transgenic groups. Overall,
these data suggest activation of collaborative oncogenic
signaling pathways contributing to the more-aggressive
growth phenotype of the MMTV-Wnt/ILK tumors.
Transcriptional profiling of transgenic mammary tumors
To identify other possible signaling molecules and events
involved in increased tumor incidence in MMTV-Wnt/
ILK transgenic tumors, we performed global gene-
expression analysis on RNA isolated from four indepen-
dent tumors from each MMTV-Wnt1 and MMTV-Wnt/
ILK transgenic model. Gene-expression levels were
determined by using the Affymatrix GeneChip Mouse
Exon 1.0 ST. The exploratory expression data obtained
from the Affymetrix scanner were processed by using
ArrayAssist software (ArrayAssist v1.x) controlling for
false-negative and false-positive results. Probe-set sum-
mary and background correction of expression values
were performed by using the RMA algorithm (ArrayAs-
sist ExonRMA), and chip-to-chip variation was corrected
by using quantile normalization. From the gene-chip
data, we identified 200 known or predicted genes show-
ing a significant fold change (data not shown). Volcano or
scatterplot was used to highlight the most differentially
expressed transcripts as the function of significance
(determined based on P value) over differential expres-
sion (determined as fold change) (Additional file 1, Figure
S3). Subsequently, all exon-level and gene-level probe sets
showing an absolute fold change > 2.5 and an unadjusted
P value < 0.05 were reviewed (Table S1). Categorization
of these differentially expressed genes according to their
molecular-function groups, as shown in Additional file 2,
suggests a change in the program of gene expression, and
particularly a transcriptionally active signaling network in
Wnt/ILK mammary tumors (Additional file 2). Included
among these are Sirt1, Hey2, Ncoa4, and Foxa1, all of
which have been implicated in the progression of luminal
breast cancer and ER-α-dependent signaling, as well as
ER-α (that is, Esr 1) (Additional file 2). Ncoa4 (nuclear
receptor co-activator 4) and FOXA1 (forkhead-box A1),
both have been shown to act as transcriptional activators
of estrogen (ER)-α [36,37]. Sirt1 transcription factor has
been shown to regulate Hey2, a downstream effecter of
Notch1 signaling [38,39], one of the more prominent acti-
vated pathways in the luminal-restricted mammary pro-
genitor cells [40,41]. This functional classification also
facilitated the selection of the gene candidates for further
validation (Additional file 2). This microarray analysis
with the limited number of chips used was an initial
approach in obtaining an exploratory list of potential
gene targets. We, therefore, followed up by selecting 26 of
these genes for validation by quantitative reverse tran-
scriptase PCR (Q-RT-PCR).
Transcript levels for each test gene were normalized to
β-actin or GAPDH transcript levels or both in the same
extract. Logarithmic results were exponentiated to obtain
linear-scale fold-change estimates (that is, 2-ΔΔCt) and
confidence intervals. The results of the Q-RT-PCR assays
demonstrated consistent differential expression for 17 of
Figure 4 Biochemical analysis, densitometry results, and immu-
nochemistry. (a) The biochemical analysis of the tumors from each 
group demonstrates upregulation of certain molecular markers in 
MMTV-Wnt/ILK tumors, which could potentially lead to the more-ag-
gressive growth phenotype observed in these tumors. The lysates 
from two different FVB mammary glands were used as controls. The 
blots were generated at the same time, by using the same apparatus, 
and under identical exposure times and conditions to ensure compa-
rability. (b) The graph for the Western-blot analysis illustrates the den-
sitometry results of the blots. Results represent the mean of 
densitometry data from 10 independent tumors normalized for β-actin 
expression. The error bars represent the standard error of the mean 
(SEM). *P ≤ 0.05; **P < 0.005; calculated by using an ANCOVA analysis. 
(c) β-catenin immunohistochemistry shows a significant increase in 
nuclear localization in excised tumors from MMTV-Wnt/ILK mice, sug-
gesting a more-active β-catenin-mediated transcriptional machinery. 
Magnification: (a,b) 40×; (c,d) 63×; n = 4. β-catenin staining of the nor-
mal FVB mammary gland is included as a control (e,f). Scale bars, 25 
μm. (d) Positive nuclear β-catenin staining was determined by count-
ing the cells that showed overlapping hematoxylin and β-catenin 
staining. The cells were counted in five equal randomly chosen fields 
of view at 40× magnification in four individual tumors. Results are re-
ported as the mean of the ratio of the total number of the nuclear-pos-
itive cells to the total cell count. The error bars represent the standard 
error of the mean (SEM). **P < 1.1 × 10-7 was calculated by using a 
paired two-sample t test.Oloumi et al. Breast Cancer Research 2010, 12:R38
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the 26 genes identified and tested from the Affymetrix
analysis (Figure 5).
MMTV-Wnt/ILK transgenic mice develop tumors enriched 
for luminal progenitor cells and active FOXA1/ER-α 
network
Expression profiling, by microarray DNA analysis,
revealed a marked upregulation in FOXA1 in mammary
carcinomas of the Wnt/ILK double-transgenic mice
(T able S1). Upregulation of FOXA1 also was confirmed
by Q-RT-PCR in a larger tumor sample set (n = 8) as well
as at the protein level by immunohistochemical staining
(Figure 6). Quantitative RT-PCR showed an average
increase of fourfold in FOXA1 expression (Figure 5). The
fact that FOXA1 controls the downstream transcription
of ER-regulated genes [37,42,43] led us to examine fur-
ther the expression of ER-α, which was also identified in
the Affymetrix analysis. ER-α also showed evidence of
fold change in our exon-level analysis on eight different
exon probe sets, with an average fold change of 2.56 and a
P value of 0.031.
At the protein level, although the tumors from both
transgenic models were ER-α positive by immunohis-
tochemistry, a higher level of staining was evident in sec-
tions from the double-transgenic tumors (Figure 6a). In
addition, Q-RT-PCR revealed a 2.4-fold increase in ER-α
expression at the mRNA level in MMTV-Wnt/ILK
tumors (Figure 6b). Because the expression of ER-α is
considered one of the hallmarks of luminal-type breast
tumor [42], and FOXA1 is considered a marker of luminal
cell differentiation during normal mammary gland devel-
opment [44], we sought to examine the potential differ-
ence in the level of mammary gland luminal epithelial
fraction in the two transgenic models.
Recently, CD24 was used as a single marker for isola-
tion of pure populations of the luminal and basal com-
partments of the mouse mammary epithelium. Cells with
a high expression of CD24 were identified to represent
the mouse mammary luminal epithelial cells [41,45,46].
Other studies showed high expression of CD24 on lumi-
nal-restricted colony-forming cells [41,45,46]. In our
model, initial immunohistochemistry revealed a greater
p r e s e n c e  o f  C D 2 4 - p o s i t i v e  c e l l s  i n  b o t h  m a m m a r y
tumors and pre-neoplastic mammary glands of MMTV-
Wnt/ILK mice compared with the same tissue type in
MMTV-Wnt mice (data not shown). This suggests a pos-
sible role for ILK in the background of MMTV-Wnt1 in
expanding the luminal cell lineage with markedly
enriched tumor-forming capacity.
However, because analysis of CD24 level by IHC is not
an optimal way for such a comparison to be made, we fur-
ther examined different epithelial subpopulations in
tumors from both transgenic models with FACS analysis.
We specifically looked at the expression of the cell-sur-
face markers CD24 and CD61 within the Lin-CD29lo frac-
tion (Figure 7a). Within the CD29loCD24hi fraction, also
known as the luminal subpopulation [47], we determined
the level of CD61+, which is the enriched fraction for the
luminal progenitor cells [8,48] (Figure 7a). Single-cell sus-
pensions from mammary glands of FVB mice were used
as a control for staining with these cell-surface markers
Figure 5 Q-RT-PCR validation of the microarray data shows dif-
ferential expression of 17 of 26 genes tested (at least three and 
up to eight samples). Results were exponentiated to obtain natural-
scale fold-change estimates (that is, 2-ΔΔCt) and 95% confidence inter-
vals, shown as bar heights and whiskers, respectively. The genes that 
showed a fold change of ≥ 30% with P ≤ 0.05 are presented as validat-
ed genes.
Figure 6 Immunohistochemical staining and PCR analysis. (a) Im-
munohistochemical staining of tumors from MMTV-Wnt/ILK mice ex-
hibit strikingly enhanced expression of FOXA1 and ER-α. 
Magnifications: (a,d) 40×; (b,c, and e,f) 63×. Scale bars, 50 μm. (b) Q-
RT-PCR analysis shows a 2.4-fold increase in ER-α transcripts levels in 
MMTV-Wnt/ILK tumors. Results are shown as fold change (FC) of ER-α 
expression in MMTV-Wnt/ILK over MMTV-Wnt1 tumors.Oloumi et al. Breast Cancer Research 2010, 12:R38
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(Figure 7a). As suspected, single-cell suspensions pre-
pared from MMTV-Wnt/ILK tumors (n = 3), depleted of
hematopoietic and endothelial cells [8] (referred to as
"Lin-"), showed a more than two fold expansion in the
percentage of CD61+ luminal progenitor cells within the
total luminal fraction, CD29loCD24hi population (Figure
7a,b). The purity of the cell populations was evaluated by
determining the expression of the luminal lineage marker
keratin 18 (K18) and the myoepithelial marker keratin 14
(K14) (Figure 7c). As expected, K18 expression was high-
est in the CD29loCD24hi  luminal fraction, whereas
expression of K14 was restricted to CD29hiCD24med myo-
epithelial fraction in both transgenic models (Figure 7c).
These data further suggest the expansion of the luminal
progenitor lineage as the result of the mutual input of ILK
and Wnt1 signaling.
Discussion
Transgenic and knockout mice bearing genetic changes
have been used as the conventional approaches to test
some of the signaling events involved in the induction
and progression of breast cancer. ILK- and Wnt-mediated
signaling are two such pathways. Cooperative signaling
between ILK and Wnt in cell culture was identified by us
earlier [17,49]. In this study, we showed that mammary-
specific expression of ILK in MMTV-Wnt1 mice results
in the accelerated development of the spontaneous mam-
mary tumors. Enhanced expression of pro-proliferative
genes, such as β-catenin  and  cyclin D1, are evident in
these double-transgenic mice. We also present several
lines of evidence supporting the notion that the coopera-
tive signaling events between Wnt1 and ILK pathways
result in a highly active ER-α signaling pathway. The
molecular signature of MMTV-Wnt/ILK tumors con-
Figure 7 Flow-cytometry analysis and relative proportions of cell types. (a) Flow-cytometry analysis showing the distribution of Lin-CD29lo for 
the expression of the surface markers CD24 and CD61. Mammary glands from 10-week-old FVB mice were included as a control for the expression of 
these cell-surface markers and analysis by FACS. The increase in CD24hiCD61+ luminal progenitor cells is evident in the tumor cells of the MMTV-Wnt/
ILK transgenic model compared with MMTV-Wnt (n = 3 per group). (b) Bar chart depicting the relative proportion of the CD61+ luminal progenitor 
cells to the total luminal population (CD29loCD24hi) in the two tumor types. Error bars indicate mean ± SD. **P < 0.002 was calculated by using a paired 
two-sample t test. (c) The purity of the cell populations (myoepithelial and luminal) in the sorted fractions is shown by the lineage-specific markers, 
K18 and K14, in the cultured tumor cells of both transgenic models. Scale bars, 25 μm.Oloumi et al. Breast Cancer Research 2010, 12:R38
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tained the transcripts of several proteins involved in ER-α
signaling. Among those is FOXA1, which shows an aver-
age fourfold increase in expression in double-transgenic
mammary tumors compared with Wnt1 tumors with >
95% confidence interval. Even though the transcriptional
regulation of FOXA1 remains a subject of further investi-
gation, earlier studies show positive regulation of FOXA1
by activated β-catenin through Sox17 [50]. Therefore, the
Wnt1/ILK-mediated upregulation of nuclear β-catenin
shown both in vitro [17] and in vivo (Figure 4) could
potentially be responsible for the observed upregulation
of FOXA1 expression in the Wnt1/ILK mammary
tumors.
Forkhead-box A1 (FOXA1), a member of the "winged
helix" family of the transcription factors, can regulate
many genes associated with regulation of cell signaling
and the cell cycle [51] and can act either as a growth stim-
ulator or as a repressor. As a stimulator, FOXA1 interacts
with cis-regulatory regions in heterochromatin and opens
the chromatin [52], which subsequently enhances the
interaction of ER-α with promoters of various ERα-regu-
lated genes. Transactivations of ER-α machinery, as well
as the enhancement in nuclear accumulation of β-
Catenin also support the observed upregulation of cyclin
D1 in Wnt1/ILK double-transgenic mammary tumors.
Cyclin D1 is one of the most commonly overexpressed
genes in human breast cancer whose transcription is acti-
vated by FOXA-1-mediated ER-α gene regulation [53,54],
as well as by β-catenin-mediated transcriptional machin-
ery [55]. Although the enhancement in cyclin D1 upregu-
lation is not apparent at the transcript level with our
microarray analysis, it is noteworthy that this approach
was applied as the initial exploratory finding, and the
small sample size used is not necessarily the best repre-
sentative of some of the subsequent differences explored
in this study.
Our gene-expression profiling also shows a significant
decrease in multiple androgen receptor (AR) transcripts
in MMTV-Wnt/ILK tumors (Additional file 3), which
also supports the notion of more-active ER-α signaling
machinery. Decreased AR signaling has been shown to
correlate with an increase in ER-α transactivation as the
result of shared co-activator proteins [56]. One such co-
activator is identified as ARA70 or NcoA4 [36], another
one of the genes identified in our expression analysis to
be upregulated in MMTV-Wnt/ILK tumors. Overall,
these results suggest a potential role for activated ER-
mediated signaling in the biology of these fast-growing
double-transgenic tumors.
Although hierarchic cluster analysis of breast-tumor
subtypes with distinct gene-expression patterns has asso-
ciated ER-α positive and FOXA1 expression with luminal
subtypes [57], recently, aberrant luminal progenitors,
positive for ER-α expression, were identified as the target
of transformation for certain human basal tumors [58]. In
our model, FACS profile analysis of tumor cells from the
double-transgenic mice also clearly shows an expansion
in the CD29loCD24hiCD61+  luminal progenitor cells.
T h e s e  r e s u l t s ,  a l o n g  w i t h  a  m a r k e d  i n c r e a s e  i n  C D 2 4
expression in MMTV-Wnt/ILK tumors, provides evi-
dence for tumors arising from the luminal lineage.
Whereas CD24 expression has been implicated in multi-
ple cell properties of direct relevance to tumor growth,
such as tumor-cell proliferation [59], its high expression
has been reported on luminal-restricted mouse mam-
mary progenitor cells [48,60] and, more recently, on
human luminal-restricted progeny through cluster analy-
sis of gene-expression profiling [41]. Interestingly, some
of our other data, such as enhancement of the down-
stream effectors of Notch1 signaling, Hey2 and Sirt1, fur-
ther support the expansion of the population of the cells
from the luminal lineage in MMTV-Wnt/ILK mammary
glands and tumors. Notch1 and its target genes were
recently shown to be preferentially active in both mouse
and human mammary luminal progenitor cells in vivo
[41]. Notably, ILK activity has been identified as a prosur-
vival event upstream of Notch1 signaling in a leukemic
microenvironment [61]. Therefore, the cooperative
events between Wnt and ILK signaling are likely to target
the luminal progenitor cells for expansion and self-
renewal as the initial steps during transformation. This
provides a likely explanation for a mechanism involved in
accelerated tumor development and growth identified in
this model.
These results, together with the molecular-profiling
analyses presented in this work, implicate luminal pro-
genitor cells as the probable target population in MMTV-
Wnt/ILK mammary tumors with extensive proliferation
capacity.
Last, about 70% of human breast cancers are pheno-
typed as ER positive and are classified as the "luminal epi-
thelial-like/ER-positive" subtype, which express high
levels of ER-α and genes regulated by estrogen. However,
it is clear that ER-positive tumors do not represent a sin-
gle entity [58,62]. Therefore, identification of distinct
progenitor cell populations with different hormonal sen-
sitivities in the backbone of certain signaling events, such
as cyclin D1, is an important step in determining the cel-
lular origin of certain types of breast cancer and the suc-
cessful development of targeted therapies.
Conclusions
The exact contribution of different cell types and onco-
genic mutations to breast cancer heterogeneity remains
unknown. Here, we report novel crosstalk between ILK
and Wnt1 oncogenes, resulting in accelerated breast can-
cer development with molecular characteristics consis-
tent with a more-aggressive phenotype in vivo. TheOloumi et al. Breast Cancer Research 2010, 12:R38
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Wnt1/ILK transgenic model of mammary tumor devel-
opment shows evidence of expansion of the luminal pro-
genitor cells with a highly active ER-α transcriptional
network. This could serve as model to study ER-α/
FOXA1-mediated gene regulation, and to refine further
the molecular classification of ER(+)-type breast cancers.
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